Clinical Trial Search

Primary: Annualized Relapse Rate (ARR) — 0.10; 0.25 number of relapses in a year — p=<0.001

Primary: Seroprotection Rate Three and Four Years After Initial Vaccination With CD-JEV — 9.2; 9.8; 9.3; 12.5 percentage of participants

Primary: Number of Participants With Signal Intensity (SI) Change of a Lymph Node Between the Pre- and Post- Contrast of the Feraheme Enhanced Magnetic Resonance Imaging (MRI)…

Primary: First Event of Cardiovascular Death, Resuscitated Cardiac Arrest, Acute Myocardial Infarction, Stroke, or Urgent Hospitalization for Angina Requiring Coronary…

Primary: 24-hours Systolic Blood Pressure at Week 12 — 117; 120 mmHg — p=0.755

Primary: Disease Response (Complete, Complete Unconfirmed, and Partial Responses) After 4 Courses — 47; 8; 14 Participants

Primary: Change in Craving to Use Alcohol Rating (Visual Analog Scale) — 0.076; -0.928 score on a scale

Primary: Subjective Tooth Assessment: Number of Teeth With Normal and Abnormal Pulp — 111; 32 Teeth

Primary: Part A: Number of Participants Reporting Local Reactogenicity Signs and Symptoms During the Primary Vaccine Regimen — 42; 26; 126; 16 Participants

Primary: Number of Subjects With Dose Limiting Toxicities — 0 Participants

Primary: Subjective Overall Comfort Rating — 8.2; 8.6; 8.3; 8.3 units on a scale

Primary: Percentage of Participants With Treatment-Emergent Adverse Events (TEAEs) — 100; 97.9; 14.7; 18.8 percent of participants

Primary: Tumor Response Rate (RR) (Percentage of Participants Exhibiting Complete Response [CR] or Complete Response Unconfirmed [CRu] or Partial Response [PR]) — 0; 0; 0; 0…

Primary: Number of Participants Reporting Substance Use — 38; 45; 8; 9 Participants

Primary: Intraocular Pressure (IOP) — 20.5; 20.3; 20.8; 21.1 mmHg — p=<0.0001